RESUMEN
Abstract Fascioliasis is a food-borne anthropozoonotic disease caused by Fasciola hepatica that affects multiple hosts, including humans. We herein report the first case of human fascioliasis in the state of Santa Catarina, Brazil. A 57-year-old female patient complaining of abdominal pain was admitted to the hospital for a clinical investigation. The diagnosis of F. hepatica was confirmed by ultrasound and indirect enzyme-linked immunosorbent assay. Authorities of the Northern coast of Santa Catarina were notified to investigate other cases and risk factors for contamination. The disease is also prevalent in cattle, which could pose as a potential route for infection.
Asunto(s)
Humanos , Animales , Femenino , Fasciola hepatica/inmunología , Fascioliasis/diagnóstico , Brasil , Ensayo de Inmunoadsorción Enzimática , Imagen por Resonancia Magnética , Ultrasonografía , Sensibilidad y Especificidad , Persona de Mediana EdadRESUMEN
A aterosclerose é uma doença caracterizada por inflamação vascular, sendo a proteína C-reativa ultrassensível, a interleucina-6 e o óxido nítrico, alguns de seus marcadores, e cujas complicações incluem o infarto agudo do miocárdio e o acidente vascular cerebral. Uma das principais causas de aterosclerose é a dislipidemia. O cilostazol atua como vasodilatador, antiagregante de plaquetas e antitrombótico. Essa droga também promove a diminuição de triglicerídeos e o aumento de lipoproteínas de alta densidade em diabéticos e em doentes com doença arterial obstrutiva periférica, podendo interferir na aterosclerose. Baseados nesses dados, há a possibilidade de efeitos benéficos do cilostazol na lipemia pós-prandial, nos mediadores da inflamação e na função endotelial.
Atherosclerosis is a disorder that is characterized by vascular inflammation, with ultra-sensitive C-reactive protein, interleukin-6 and nitric oxide being some of its biomarkers, and whose complications include acute myocardial infarction and stroke. One of the main causes of atherosclerosis is dyslipidemia. Cilostazol acts as a vasodilator, antiplatelet, and antithrombotic agent. It also promotes triglycerides decrease and high density lipoproteins increase in diabetics and in patients with obstructive peripheral arterial disease, potentially interfering with atherosclerosis. Based on these data, cilostazol may have beneficial effects on postprandial lipemia, inflammatory mediators, and endothelial function.